Venture Partners Select Iv,... Net Worth

The estimated Net Worth of Venture Partners Select Iv,... is at least 28.3 千$ dollars as of 2 March 2022. Venture Iv owns over 314,750 units of Personalis Inc stock worth over 28,263$ and over the last 3 years Venture sold PSNL stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Iv PSNL stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Personalis Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Venture bought 314,750 units of PSNL stock worth 3,103,435$ on 2 March 2022.

The largest trade Venture's ever made was buying 314,750 units of Personalis Inc stock on 2 March 2022 worth over 3,103,435$. On average, Venture trades about 314,750 units every 0 days since 2022. As of 2 March 2022 Venture still owns at least 4,750 units of Personalis Inc stock.

You can see the complete history of Venture Iv stock trades at the bottom of the page.

Insiders trading at Personalis Inc

Over the last 5 years, insiders at Personalis Inc have traded over 56,423,548$ worth of Personalis Inc stock and bought 5,708,990 units worth 54,066,334$ . The most active insiders traders include Llp Abingworth、Paul Ricci、Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of 410,996$. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth 17,745,000$.

What does Personalis Inc do?

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Complete history of Venture Iv stock trades at Personalis Inc

Personalis Inc executives and stock owners

Personalis Inc executives and other stock owners filed with the SEC include:

• Aaron Tachibana,
  Chief Financial Officer
• Clinton Musil,
  Chief Business Officer
• John Stephen West,
  Co-Founder, CEO, Pres & Director
• Paul Ricci,
  Independent Director
• John West,
  President, Chief Executive Officer, Director
• Dr. Richard Chen M.D., M.S., MS,
  Sr. VP of R&D and Chief Medical Officer
• Richard Chen,
  Chief Science Officer
• Aaron L. Tachibana,
  Sr. VP & CFO
• Dr. Richard Chen M.S., M.D., MS,
  Chief Scientific Officer
• A. Blaine Bowman,
  Independent Director
• Alan Colowick,
  Independent Director
• Karin Eastham,
  Independent Director
• Jonathan MacQuitty,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Patrick Balthrop,
  Independent Director
• Stephen Moore,
  General Counsel
• Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Michael J. Fitzpatrick,
  VP of Worldwide Sales
• Stephen M. Moore J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Carol J. Tillis,
  VP of Fin. & Admin.
• Dr. Michael Snyder Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Atul Butte,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Kenneth J Widder,
  
• Olivia Kyusuk Bloom,
  
• Ken Ludlum,
  Director
• Mdv Partners, L.L.C.Mdv Ix ...,
  
• Venture Partners Viii Lp Li...,
  
• Venture Partners Select Iv,...,
  
• Llp Abingworth,
  
• Christopher M Hall,
  PRESIDENT AND CEO
• Venture Partners Select Iv,...,
  
• Ai, Inc. Tempus,
  10% owner
• Lonnie Shoff,